Add like
Add dislike
Add to saved papers

Variation of CD4 + CD25 + Foxp3 + Regulatory T Cells and Th17 Cells in the Peripheral Blood of Human Liver Allograft Patients With Long-term Survival.

BACKGROUND: Monitoring of peripheral blood (PB) lymphocyte subpopulation counts may be useful to underlie immune status after liver transplantation (LT). We aimed at exploring the variation of regulatory cells and Th17 in the PB of liver allograft patients with long-term survival.

METHODS: Forty-two patients who took FK506 drugs were divided into 3 groups: patients who survived for 6 months to 3 years were in the Tac1 group (n = 15), those who survived for 3-10 years were in the Tac2 group (n = 15), and those who survived for >10 years were in the Tac3 group (n = 12). Healthy individuals were recruited in the control group (n = 20). Liver function was tested. Peripheral blood mononuclear cells (PBMCs) were separated. T-cell subpopulations were analyzed using flow cytometry.

RESULTS: No difference in liver function indicators was observed compared with all the groups. Treg percentages in CD4+ T cells were significantly down-regulated in Tac1, Tac2, and Tac3 versus the control group; Tregs/CD4+ T ratio in Tac2 and Tac3 were even lower versus that in the Tac1 group. Th17 percentages in CD4+ T cells showed no difference compared with Tac3 and control, compared with Tac1, Tac2, and Tac3 groups. Liver allograft patients with long-term survival had normal liver function same as healthy individuals. With survival time increasing, the ratio of Tregs/CD4+ T cells was significantly reduced and the ratio of Th17/CD4+ T cells was kept almost unchanged in the stable postoperational patients under FK506 immunosuppression.

CONCLUSIONS: Our work enriched our understanding of Tregs in the solid organ transplantation field.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app